Kala Pharmaceuticals announced that the California Institute for Regenerative Medicine, CIRM, has awarded Combangio, a wholly owned subsidiary of Kala, a $15 million grant to support its ongoing KPI-012 program for the treatment of persistent corneal epithelial defect, PCED. The grant includes funding for the CHASE, Corneal Healing After SEcretome therapy, Phase 2b clinical trial as well as product and process characterization and analytical development for the program. "We are honored that CIRM has recognized KPI-012’s potential to correct impaired corneal healing," said Mark Iwicki, Chief Executive Officer and Chairman of Kala Pharmaceuticals. "We believe this grant not only serves as further validation for KPI-012 and our MSC-S platform, but will provide us with important funding to advance our ongoing Phase 2b trial, which could serve as the first of two pivotal trials needed to support the submission of a BLA to the FDA."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on KALA:
- Kala Pharmaceuticals price target raised to $22 from $20 at H.C. Wainwright
- Kala Pharmaceuticals receives FDA Fast Track designation for KPI-012
- Kala Pharmaceuticals appoints Francis Mah as chief medical advisor
- Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED
- Kala announces safety update from Cohort 1 of CHASE Phase 2b trial
